A longitudinal study of cognitive functioning in schizophrenia: Clinical and biological predictors

被引:21
作者
Dickerson, Faith [1 ]
Schroeder, Jennifer [2 ]
Stallings, Cassie [1 ]
Origoni, Andrea [1 ]
Katsafanas, Emily [1 ]
Schwienfurth, Lucy A. B. [1 ]
Savage, Christina L. G. [1 ]
Khushalani, Sunil [1 ]
Yolken, Robert [3 ]
机构
[1] Sheppard Pratt Hlth Syst, Stanley Res Program, Baltimore, MD USA
[2] Schroeder Stat Consulting LLC, Ellicott City, MD USA
[3] Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA
关键词
Cognitive; Schizophrenia; Longitudinal; METHYLTRANSFERASE VAL158MET POLYMORPHISM; SIMPLEX-VIRUS TYPE-1; NEUROPSYCHOLOGICAL STATUS; NEUROCOGNITIVE DEFICITS; REPEATABLE BATTERY; FOLLOW-UP; INDIVIDUALS; IMPAIRMENT; PERFORMANCE; ANTIBODIES;
D O I
10.1016/j.schres.2014.04.019
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Cognitive deficits are a central feature of schizophrenia but it is not certain how cognitive functioning changes over time. The purpose of this prospective longitudinal study was to determine the temporal change of cognitive functioning and the predictors of cognitive performance from among demographic, clinical, and biological variables. Methods: Participants were individuals with schizophrenia or schizoaffective disorder whose cognitive functioning was assessed at multiple time points with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). At the baseline visit participants had a blood sample drawn from which C-reactive protein, antibodies to Herpes Simplex Virus type 1, and selected genetic polymorphisms were measured. Repeated measures linear regression was used to determine whether cognitive measures changed over time and which variables predicted cognitive performance. Results: The sample consisted of 132 participants, mean age 43.7 years at baseline, who received a median of 3 cognitive assessments over a period averaging 2.8 years. The RBANS Total score and Language index showed no statistically significant temporal change; performance on two indices, Immediate Memory and Attention, showed modest but statistically significant improvements (gains of 0.89 +/- 0.33 and 0.76 +/- 0.29 points per year, respectively); Visuospatial/Constructional performance showed a modest but statistically significant decline (of 0.80 +/- 0.25 points per year). Few variables predicted cognitive performance; however greater psychiatric symptom severity was associated with worse cognitive performance for most cognitive measures. Conclusions: Cognitive functioning in middle-aged persons with schizophrenia showed an absence of decline for most measures and modest gains in some measures. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:248 / 253
页数:6
相关论文
共 38 条
[1]   INTELLECTUAL DEFICITS IN 1ST-EPISODE SCHIZOPHRENIA - EVIDENCE FOR PROGRESSIVE DETERIORATION [J].
BILDER, RM ;
LIPSCHUTZBROCH, L ;
REITER, G ;
GEISLER, SH ;
MAYERHOFF, DI ;
LIEBERMAN, JA .
SCHIZOPHRENIA BULLETIN, 1992, 18 (03) :437-448
[2]   Neurocognition in schizophrenia: a 20-year multi-follow-up of the course of processing speed and stored knowledge [J].
Bonner-Jackson, Aaron ;
Grossman, Linda S. ;
Harrow, Martin ;
Rosen, Cherise .
COMPREHENSIVE PSYCHIATRY, 2010, 51 (05) :471-479
[3]  
Bora E, 2013, SCHIZOPHR B
[4]   Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up [J].
Dickerson, F ;
Boronow, JJ ;
Ringel, N ;
Parente, F .
SCHIZOPHRENIA RESEARCH, 1999, 37 (01) :13-20
[5]   The lymphotoxin Cys13Arg polymorphism and cognitive functioning in individuals with schizophrenia [J].
Dickerson, Faith ;
Boronow, John ;
Stallings, Cassie ;
Origoni, Andrea ;
Yolken, Robert .
SCHIZOPHRENIA RESEARCH, 2007, 89 (1-3) :173-176
[6]   Additive effects of elevated C-reactive protein and exposure to Herpes Simplex Virus type 1 on cognitive impairment in individuals with schizophrenia [J].
Dickerson, Faith ;
Stallings, Cassie ;
Origoni, Andrea ;
Vaughan, Crystal ;
Khushalani, Sunil ;
Yolken, Robert .
SCHIZOPHRENIA RESEARCH, 2012, 134 (01) :83-88
[7]   Artemisinin reduces the level of antibodies to gliadin in schizophrenia [J].
Dickerson, Faith ;
Stallings, Cassie ;
Vaughan, Crystal ;
Origoni, Andrea ;
Goga, Joshana ;
Khushalani, Sunil ;
Yolken, Robert .
SCHIZOPHRENIA RESEARCH, 2011, 129 (2-3) :196-200
[8]   The catechol O-methyltransferase Val158Met polymorphism is not associated with broad-based cognititive functioning in schizophrenia [J].
Dickerson, Faith B. ;
BoronoW, John J. ;
Stallings, Cassie ;
Origoni, Andrea E. ;
SullenS, Anne ;
Yolken, Robert H. .
SCHIZOPHRENIA RESEARCH, 2007, 96 (1-3) :87-92
[9]   A double-blind trial of adjunctive azithromycin in individuals with schizophrenia who are seropositive for Toxoplasma gondii [J].
Dickerson, Faith B. ;
Stallings, Cassie R. ;
Boronow, John J. ;
Origoni, Andrea E. ;
Yolken, Robert H. .
SCHIZOPHRENIA RESEARCH, 2009, 112 (1-3) :198-199
[10]   A double-blind trial of adjunctive allopurinol for schizophrenia [J].
Dickerson, Faith B. ;
Stallings, Cassie R. ;
Origoni, Andrea E. ;
Sullens, Anne ;
Khushalani, Sunil ;
Sandson, Neil ;
Yolken, Robert H. .
SCHIZOPHRENIA RESEARCH, 2009, 109 (1-3) :66-69